Trials by therapeutic agent

Fluvoxamine clinical trials

3 post-viral trials on ClinicalTrials.gov · updated October 2026

Last updated 07 October 2026 from ClinicalTrials.gov. Trial statuses are refreshed automatically; check the registry record for the latest status and contact details.

3 trials1 open to enrolment2 completed

All interventional trials in our ClinicalTrials.gov extract that list Fluvoxamine as an intervention, across Long COVID / PASC (3). 1 is currently open to enrolment and 2 have completed. Read the OSMF evidence profile for Fluvoxamine for literature, mechanism and dosing context.

Intervention names are normalised from the registry's own arm labels, so the same compound can appear under a brand name, a generic name or a combination; check the full agent index for related entries.

⚠️
Not medical advice. This page is an automatically compiled index of entries on ClinicalTrials.gov. Listing here is not an endorsement of any trial, sponsor or treatment, and trial status can change between our refreshes. Always confirm details on ClinicalTrials.gov and discuss participation with your own clinician.

Recruiting (1)

RecruitingPhase 3 NCT07359482
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Academic / non-profit / other)
Intervention(s): Fluvoxamine
Condition group: Long COVID / PASC
Start: Jun 2026  |  Primary completion: Dec 2027  |  Enrollment: 160 (estimated)
Record last updated: Jun 2026

Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed.

View on ClinicalTrials.gov ↗

Completed (2)

CompletedPhase 2 NCT05874037
Sponsor: Washington University School of Medicine (Academic / non-profit / other)
Intervention(s): Fluvoxamine
Condition group: Long COVID / PASC
Start: May 2023  |  Primary completion: Mar 2025  |  Enrollment: 191 (actual)
Record last updated: Oct 2026

This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials).

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT04510194
Sponsor: University of Minnesota (Academic / non-profit / other)
Intervention(s): Metformin, Fluvoxamine, Ivermectin
Condition group: Long COVID / PASC
Start: Jan 2021  |  Primary completion: Dec 2022  |  Enrollment: 1323 (actual)
Record last updated: Apr 2026

1. The purpose of this trial is to conduct a 2x3 factorial randomized trials, which efficiently allows the parallel conduct of three randomized trials to understand whether metformin, ivermectin, or fluvoxamine, is superior to placebo for preventing Covid-19 disease progression in non-hospitalized adults with SARS- CoV-2 infection. 2.

View on ClinicalTrials.gov ↗

Frequently asked questions

How do I join a clinical trial?

Open the trial's ClinicalTrials.gov record (the "View on ClinicalTrials.gov" button), read the Eligibility Criteria and Contacts and Locations sections, and contact the study team listed there. Trials only enrol at the sites shown in the record, so check whether a site is near you or whether the study is remote/decentralised. Your own clinician can help you judge whether a trial is a sensible option and may need to provide medical records.

What do the trial phases mean?

Early Phase 1 / Phase 1 studies test safety and dosing in a small group. Phase 2 studies look for a signal of benefit in a larger group and keep checking safety. Phase 3 studies are large confirmatory trials designed to show whether a treatment works well enough for approval. Phase 4 studies follow approved treatments after they reach the market. "Phase not applicable" is used by the registry for behavioural, device, rehabilitation and other non-drug interventions.

Does the Open Source Medicine Foundation run these trials?

No. OSMF does not sponsor, run or recruit for any trial on this page. We compile public registry entries from ClinicalTrials.gov so patients and clinicians can find them in one place. For questions about a specific study, contact the sponsor or study team listed on its ClinicalTrials.gov record.

Get new recruiting trials in your inbox.

We summarise newly registered post-viral trials and notable results on the OSMF Substack.

Subscribe on Substack
Cite this page
Open Source Medicine Foundation. Fluvoxamine clinical trials for Long COVID, ME/CFS and post-viral illness (3 trials, updated October 2026). Research Tracker, 07 October 2026. https://research.opensourcemed.info/trials/by-agent/fluvoxamine.html
Underlying dataset (JSON, CC BY 4.0): https://research.opensourcemed.info/data/clinical_trials/clinical_trials_current.json. Source records: ClinicalTrials.gov.

Related: all agents · recruiting Long COVID trials · recruiting ME/CFS trials · open in trial finder.